Global Neuroendocrine Tumors Market Size, Share, and COVID-19 Impact Analysis, By Product (Somatostatin Analogs, Targeted Therapy, and Chemotherapy), By End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Neuroendocrine Tumors Market Insights Forecasts to 2035

• The Global Neuroendocrine Tumors Market Size Was Estimated at USD 3.52 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 10.30% from 2025 to 2035
• The Worldwide Neuroendocrine Tumors Market Size is Expected to Reach USD 10.35 Billion by 2035
• Asia Pacific is Expected to Grow the Fastest during the forecast period.

The Global Neuroendocrine Tumors Market Size was worth around USD 3.52 Billion in 2024 and is Predicted to Grow to Around USD 10.35 Billion by 2035 with a Compound Annual Growth Rate (CAGR) of 10.30% from 2025 and 2035. The ongoing development and use of highly targeted medicines and precision medicine techniques is a noteworthy and rapidly growing trend in the worldwide neuroendocrine tumors (NETs) market. 

Market Overview

The global industry devoted to the diagnosis, management, and treatment of neuroendocrine tumors, rare cancers originating from neuroendocrine cells found throughout the body, is known as the neuroendocrine tumors (NETs) market. The market for neuroendocrine tumors (NETs) is expanding as a result of improvements in diagnosis and therapy. Pharmaceuticals, diagnostic equipment, and treatment modalities such as immunotherapies, targeted treatments, and somatostatin analogs are all included in the neuroendocrine tumors market.

The market for neuroendocrine tumors (NETs) offers opportunities due to developments in targeted treatments, more financing for research, better diagnostics, and more awareness. For Instance, in November 2023, the first-in-human clinical trial of CAR T cell therapy for neuroendocrine tumors (NETs) is expected to start, marking a major advancement in cancer treatment, according to the Neuroendocrine Tumor Research Foundation. The preclinical, early-stage research that produced this treatment was funded by NETRF.   

Significant improvements in diagnostic methods, the ongoing development of new treatment options, and the rising incidence and prevalence of neuroendocrine tumors (NETs) worldwide are the main factors driving the increased demand in the neuroendocrine tumors market. Growing rates of neuroendocrine tumors and substantial improvements in diagnostic methods that enable earlier and more precise identification are the main drivers of the neuroendocrine tumors market.

Report Coverage

This research report categorizes the neuroendocrine tumors market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the neuroendocrine tumors market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the neuroendocrine tumors market. 

Driving Factors

The development of specialized neuroendocrine tumor centers and a trend toward interdisciplinary team approaches are being fueled by the complex and diverse character of NETs. Another factor driving market growth is a focus on meeting unmet requirements and improving the lives of NET patients. The market is also being driven by the emergence of personalized medicine strategies that are adapted to the unique features of each tumor. The market for neuroendocrine tumors is expanding due to a number of factors, including the growing number of clinical studies for novel treatments and the growing investments made in this therapeutic area by pharmaceutical and biotechnology companies.  

Restraining Factors

High treatment costs, little awareness, delayed diagnosis, and stringent regulations are some of the challenges facing the neuroendocrine tumor (NET) market. Growth is further restricted by a lack of focused medications and insufficient access to expert care.

Market Segmentation

The neuroendocrine tumors market share is classified into product and end user. 

• The somatostatin analogs segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the product, the neuroendocrine tumors market is divided into somatostatin analogs, targeted therapy, and chemotherapy. Among these, the somatostatin analogs segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Somatostatin analogs are positioned as a first-line and long-term treatment option due to their proven effectiveness in managing symptoms and preventing tumor progression in a significant percentage of somatostatin receptor-positive NETs.

• The hospitals segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end user, the neuroendocrine tumors market is divided into hospitals, specialty clinics, radiation centers, home healthcare, and others. Among these, the hospitals segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The ability to offer complex, frequently inpatient therapies like PRRT and specialty operations, as well as access to multidisciplinary teams and sophisticated diagnostic capabilities, are what propel the hospitals segment.  

Regional Segment Analysis of the Neuroendocrine Tumors Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the neuroendocrine tumors market over the predicted timeframe.

North America is anticipated to hold the largest share of the Neuroendocrine Tumors market over the predicted timeframe. The North American region is distinguished by a strong healthcare system, high healthcare spending, the presence of important biotechnology and pharmaceutical businesses, and a greater rate of NET awareness and diagnosis. The rapid adoption of cutting-edge diagnostic techniques and the growing number of innovative treatment options are driving the neuroendocrine tumor market in the United States. The NET business is further driven by the strong need for targeted medicines and personalized medicine techniques, as well as the growing preference for specialist care centers.

Asia Pacific is expected to grow at a rapid CAGR in the neuroendocrine tumors market during the forecast period. The Asia-Pacific area is being driven by increasing NET incidence, rising healthcare costs, and technological improvements in nations like China, Japan, and India in particular. The region's increasing desire to improve cancer care, bolstered by government programs encouraging the development of healthcare infrastructure, is propelling the use of cutting-edge NET treatments. Rapid urbanization, the growth of the middle class, and easier access to specialist medical facilities are the reasons why the neuroendocrine tumor market in India has the highest revenue share in Asia Pacific. 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the neuroendocrine tumors market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Lupin
• Lilly
• HUTCHMED
• GSK plc
• Pfizer Inc.
• BioSynthema Inc.
• Exact Sciences Corporation
• Ipsen Pharma
• Bionano Genomics, Inc.
• Illumina, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals, Inc.
• Advanced Accelerator Applications SA
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In March 2024, Positive topline results from the open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome, were announced today by (Nasdaq: CRNX), a clinical stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics for endocrine disorders and endocrine-related tumors.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the neuroendocrine tumors market based on the below-mentioned segments:  

Global Neuroendocrine Tumors Market, By Product

•  Somatostatin Analogs
• Targeted Therapy
• Chemotherapy

Global Neuroendocrine Tumors Market, By End User

• Hospitals
• Specialty Clinics
• Radiation Centers
• Home Healthcare
• Others

Global Neuroendocrine Tumors Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa